Psoriasis is a
skin disease characterized by abnormal keratinocyte proliferation and
inflammation. Currently, there are no cures for this disease, so the goal of treatment is to decrease
inflammation and slow down the associated rapid cell growth and shedding. Recent advances have led to the usage of
phosphodiesterase 4 (
PDE4) inhibitors for treatment of this condition. For example,
apremilast is an oral, selective
PDE4 inhibitor that is able to reduce skin
inflammation and is Food and Drug Administration (FDA)-approved to treat adults with moderate to severe
psoriasis and/or
psoriatic arthritis. However, common target-related adverse events, including
diarrhea,
nausea,
headache, and
insomnia limit the usage of this
drug. To circumvent these effects, the usage of
PDE4 inhibitors specifically designed for topical treatment, such as
CHF6001, may combine local anti-inflammatory activity with limited systemic exposure, improving tolerability. In this study, we showed that
CHF6001, currently undergoing clinical development for
COPD, suppresses human keratinocyte proliferation as assessed via
BrdU incorporation. We also observed decreased re-epithelialization in a scratch-
wound model after
CHF6001 treatment. At the molecular level,
CHF6001 inhibited translocation of phosphorylated NF-κB subunit p65, promoting loss of nuclear
cyclin D1 accumulation and an increase of cell cycle inhibitor p21. Furthermore,
CHF6001 decreased oxidative stress, measured by assessing lipid peroxidation (4-HNE adduct formation), through the inactivation of the
NADPH oxidase. These results suggest that
CHF6001 has the potential to treat skin disorders associated with hyperproliferative keratinocytes, such as
psoriasis by targeting oxidative stress, abnormal re-epithelization, and
inflammation.